Loading
A phase 1/2 trial of Brenetafusp, Pembrolizumab, Tebentafusp and Bevacizumab in advanced solid tumours, run by Immunocore Ltd, active and no longer recruiting.
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors is a phase 1/2 interventional study registered as NCT04262466 by Immunocore Ltd, with 410 participants enrolled, started 2020-02-25 and due to reach its primary completion in 2026-10. Interventions recorded: Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp and Brenetafusp and bevacizumab.
Shares Immunocore, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bevacizumab, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Bevacizumab, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bevacizumab, Pembrolizumab and the tag pipeline.